109 related articles for article (PubMed ID: 2153375)
21. In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil.
Peters GJ; van Dijk J; Laurensse E; van Groeningen CJ; Lankelma J; Leyva A; Nadal JC; Pinedo HM
Br J Cancer; 1988 Mar; 57(3):259-65. PubMed ID: 3355763
[TBL] [Abstract][Full Text] [Related]
22. Brequinar sodium: inhibition of dihydroorotic acid dehydrogenase, depletion of pyrimidine pools, and consequent inhibition of immune functions in vitro.
Simon P; Townsend RM; Harris RR; Jones EA; Jaffee BD
Transplant Proc; 1993 Jun; 25(3 Suppl 2):77-80. PubMed ID: 8390742
[No Abstract] [Full Text] [Related]
23. Role of uridine phosphorylase in the anabolism of 5-fluorouracil.
Schwartz PM; Moir RD; Hyde CM; Turek PJ; Handschumacher RE
Biochem Pharmacol; 1985 Oct; 34(19):3585-9. PubMed ID: 2996553
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase.
Chen SF; Papp LM; Ardecky RJ; Rao GV; Hesson DP; Forbes M; Dexter DL
Biochem Pharmacol; 1990 Aug; 40(4):709-14. PubMed ID: 2386542
[TBL] [Abstract][Full Text] [Related]
25. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Rückemann K; Fairbanks LD; Carrey EA; Hawrylowicz CM; Richards DF; Kirschbaum B; Simmonds HA
J Biol Chem; 1998 Aug; 273(34):21682-91. PubMed ID: 9705303
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.
Schwartsmann G; Dodion P; Vermorken JB; ten Bokkel Huinink WW; Joggi J; Winograd B; Gall H; Simonetti G; van der Vijgh WJ; van Hennik MB
Cancer Chemother Pharmacol; 1990; 25(5):345-51. PubMed ID: 2306795
[TBL] [Abstract][Full Text] [Related]
27. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites.
Peters GJ; van Groeningen CJ; Laurensse EJ; Lankelma J; Leyva A; Pinedo HM
Cancer Chemother Pharmacol; 1987; 20(2):101-8. PubMed ID: 3664929
[TBL] [Abstract][Full Text] [Related]
28. Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.
Dexter DL; Hesson DP; Ardecky RJ; Rao GV; Tippett DL; Dusak BA; Paull KD; Plowman J; DeLarco BM; Narayanan VL
Cancer Res; 1985 Nov; 45(11 Pt 1):5563-8. PubMed ID: 4053030
[TBL] [Abstract][Full Text] [Related]
29. Effects of D-glucosamine and 6-azauridine on nucleotide contents, 5-fluorouridine uptake, and cytotoxicity in TA3 mammary tumor cells.
Holstege A; Keppler D
J Natl Cancer Inst; 1986 Mar; 76(3):485-92. PubMed ID: 2419623
[TBL] [Abstract][Full Text] [Related]
30. The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Effects on lymphocyte proliferation and cytokine production.
Woo J; Lemster B; Tamura K; Starzl TE; Thomson AW
Transplantation; 1993 Aug; 56(2):374-81. PubMed ID: 8356593
[TBL] [Abstract][Full Text] [Related]
31. Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors.
DeFrees SA; Sawick DP; Cunningham B; Heinstein PF; Morré DJ; Cassady JM
Biochem Pharmacol; 1988 Oct; 37(20):3807-16. PubMed ID: 2847745
[TBL] [Abstract][Full Text] [Related]
32. Distribution of the novel anticancer drug candidate Brequinar sodium (DuP 785, NSC 368390) into normal and tumor tissues of nude mice bearing human colon carcinoma xenografts.
Shen HS; Chen SF; Behrens DL; Whitney CC; Dexter DL; Forbes M
Cancer Chemother Pharmacol; 1988; 22(3):183-6. PubMed ID: 3409452
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine.
Thomson TA; Spinella-Jaegle S; Francesconi E; Meakin C; Millet S; Flao KL; Hidden H; Ruuth E
Scand J Immunol; 2002 Jul; 56(1):35-42. PubMed ID: 12100469
[TBL] [Abstract][Full Text] [Related]
34. Effect of uridine diphosphoglucose on levels of 5-phosphoribosyl pyrophosphate and uridine triphosphate in murine tissues.
Colofiore JR; Sawyer RC; Balis ME; Martin DS
Pharm Res; 1989 Oct; 6(10):863-6. PubMed ID: 2481854
[TBL] [Abstract][Full Text] [Related]
35. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
van Laar JA; Durrani FA; Rustum YM
Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
[TBL] [Abstract][Full Text] [Related]
37. Studies on the antitumor activity and biochemical actions of cyclopentenyl cytosine against human colon carcinoma HT-29 in vitro and in vivo.
Gharehbaghi K; Zhen W; Fritzer-Szekeres M; Szekeres T; Jayaram HN
Life Sci; 1999; 64(2):103-12. PubMed ID: 10069488
[TBL] [Abstract][Full Text] [Related]
38. Depletion of blood plasma cytidine due to increased hepatocellular salvage in D-galactosamine-treated rats.
Holstege A; Manglitz D; Gerok W
Eur J Biochem; 1984 Jun; 141(2):339-44. PubMed ID: 6734601
[TBL] [Abstract][Full Text] [Related]
39. Anti-arthritic effects of KF20444, a new immunosuppressive compound inhibiting dihydroorotate dehydrogenase, on rat collagen-induced arthritis.
Kobayashi K; Nakashima A; Nagata H; Nakajima H; Yamaguchi K; Sato S; Miki I
Inflamm Res; 2001 Jan; 50(1):24-31. PubMed ID: 11235018
[TBL] [Abstract][Full Text] [Related]
40. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
